Drug development has been hampered by a high failure rate in clinical trials due to 26 suboptimal efficacy or safety issues that are not predicted by preclinical studies in model 27 systems. A key contributor to this hurdle is our incomplete understanding of how drug 28 molecules function across organ systems and species. Therefore, elucidating species-and 29 tissue-specific molecular actions of drugs can provide systems level insights into therapeutic 30 efficacy, toxicity, adverse drug reactions (ADRs), and between-species differences that are 31 necessary for more effective translational medicine. Here, we present a comprehensive drug 32 knowledgebase and analytical tool, PharmOmics, comprised of genomic footprints of drugs 33 in individual tissues from multiple species (human, mouse, and rat) based on meta-analysis of 34
Drug development has been challenging and costly over the past decades due to the 51 continuously high failure rate in clinical trials (1) . Most drugs with excellent efficacy and 52 safety profiles in preclinical studies often encounter suboptimal efficacy or safety concerns in 53 humans (2). This translational gap is likely attributable to our incomplete understanding of 54 the systems level activities of drugs in individual tissues and organ systems (3) as well as the 55 differences between humans and model systems (4). 56 57 Drug activities can be captured by gene expression patterns, commonly referred to as gene 58 signatures. By measuring how a pharmacological agent affects the gene signature of a cell or 59 a tissue type in a particular species, we can infer the cell-or tissue-specific biological 60 pathways involved in therapeutic processes or toxicological responses. This concept has 61 prompted drug repositioning studies and provided important predictions for repurposing 62 approved drugs for new disease indications (5-10). Similarly, gene signatures can reveal 63 mechanisms underlying adverse drug reactions (ADRs) and can therefore be leveraged to 64 predict these ADRs as previously shown for liver and kidney toxicity (11) (12) (13) . 65 66 A drug may affect different molecular processes between tissues, causing disease treatment 67 effects in the desired target tissue(s) but toxicity or ADRs through off-target effects in other 68 tissues. Therefore, tissue-specific drug treatment signatures will offer more systematic 69 4 understanding of drug actions in vivo. Additionally, rodent models have been commonly used 70 in toxicology and preclinical studies, yet species-specific effects of drugs has been well 71 described (14) and underlie the lack of efficacy or unexpected ADRs or toxicity responses of 72 certain drugs when used in humans (15) . Therefore, understanding the species-specific 73 molecular effects of drugs is also of high biological importance. A detailed species-and 74 tissue-specific drug genomic signature database will significantly improve our understanding 75 of the molecular networks affected by drugs and facilitate network-based drug discovery and 76 ADR prediction for translational medicine. 77
78
The tremendous potential of using gene signatures to facilitate target and toxicity 79 identification has led to several major efforts in characterizing genomic signatures related to 80 drug treatment (8, (16) (17) (18) . However, none of the existing platforms offer comprehensive 81 cross-tissue and cross-species in vivo assessments of drug activities to allow predictions of 82 the effects of a drug on individual tissues and to help assess the translational potential of a 83 drug based on consistencies or discrepancies between species. For instance, the comparative 84 toxicogenomics database (CTD), a literature-based resource curating chemical-to-85 gene/protein associations as well as chemical-to-disease and gene/protein-to-disease 86 connections (16), lacks the cellular and tissue context of the curated interactions. More 87 systematic, data-driven databases like CMAP (8) and LINC1000 (17) focus on characterizing 88 and cataloging the genomic footprints of more than ten thousand chemicals using in vitro cell 89 lines (primarily cancer cell lines) to offer global views of molecular responses to drugs in 90 individual cellular systems. However, these in vitro cell-line based gene signatures may not 91 capture in vivo tissue-specificity of drug activities. To move into the in vivo systems, large 92 6 the title or abstract fields of the dataset records. GEO and ArrayExpress datasets were 116 identified as of January 2018. Duplicated datasets between repositories were removed. We 117 developed a semi-automated pipeline combining automated search with manual checking to 118 identify relevant datasets for drug treatment. The automated process first extracts datasets 119 containing drug generic names or abbreviations and then inspects the potential datasets for 120 availability of both drug treatment and control labels in the constituent samples. We also 121 manually checked the recorded labels identified by the automated process to validate the 122 labels to decrease potential false detections. Only datasets with n>=3/group in both drug 123 treatment and control groups were included in our downstream analyses. We combined drug 124 treatment samples regardless of dose and regimen for the same drug in order to obtain the 125 consensus responses across conditions. The decision on not further stratifying the studies 126 based on dose and regimen was to increase the generalizability of the drug signatures and to 127 mitigate the reduced statistical power due to uneven coverage of dose and regimen 128 information across data repositories and drugs. 129
130
Obtaining drug treatment signatures stratified by species and tissues 131 7 "immune system", "hematopoietic system", "skeletal system", "integument" (endothelial and 139 skin tissue), "connective tissue", "muscular system", "gland", "gastrointestinal system", and 140 "viscus" (other non-classified tissue). Tissue terms relevant to each of these tissues or organs 141 were curated from the ontology tree into a tissue/organ ontology table. Next, in our 142 tissue/organ ontology table, we looked up the terms in the Cell/Organism/Tissue column of 143 the metadata in each transcriptomic dataset. If not found, we searched the title and summary 144 columns of the metadata as well to retrieve additional information. When searching returned 145 multiple tissue terms, we used the one with the higher priority order as described above. 146
Manual checking was conducted to confirm the tissue annotation for each dataset. 147
148
For each gene expression dataset, normalized data were retrieved, followed by assessment of 149 quantile distribution of values and, when data was not normally distributed, log2-150 transformation using GEO2R (20). Due to the heterogeneity of the datasets in terms of study 151 design, platforms, sample size, and normalization methods, we chose to use the characteristic 152 direction method in the GeoDE package (23) to identify genes affected by drug treatment. 153
GeoDE was designed to accommodate datasets from different settings and outputs 154 differences between treatment and control groups using a "characteristic direction" measure 155 analogous but superior to fold change in identifying biologically relevant genes and pathways. 156
The normalized characteristic directions for all genes were then transformed into a non-157 parametric rank representation. Subsequently, gene ranks of a particular drug from the same 158 tissue/organ system and the same organism were aggregated across datasets using the Robust 159
Rank Aggregation method (24) to identify differentially expressed genes (DEGs) of the drug 160 within each tissue for each species. Robust Rank Aggregation provides a non-parametric 161 8 meta-analysis across different ranked lists to obtain commonly shared genes across datasets, 162 which avoids statistical issues associated with heterogeneous datasets. It computes a null 163 distribution based on randomized gene ranks and then compares the null distribution with the 164 empirical gene ranks to obtain a p-value for each gene. The robust rank aggregation process 165 was done for the upregulated and downregulated genes separately to obtain DEGs for both Pathways at false discovery rate (FDR) <0.05 were considered significant. For cross-tissue 173 and species comparison described in this article we used all five pathway databases to make it 174 more comprehensive. 175 176 As summarized in Figure 2 , in total we identified 1,314 transcriptomic datasets across 551 177 drugs from GEO, ArrayExpress, DrugMatrix, and TG-GATEs. These datasets cover >20 178 tissue or organ systems in rats, human, and mouse and 289 KEGG drug classes. The 179 toxicogenomics databases TG-GATEs and DrugMatrix mainly deposited rat liver and kidney 180 datasets, while public data repositories GEO and ArrayExpress contained datasets with 181 broader tissue and species coverage (Figure 2A) . More liver and kidney datasets are from 182 rats whereas more human and mouse datasets are available for the other tissues ( Figure 2B) . 183
There is also a species bias between the data repositories, with GEO covering more mouse 184 9 and human datasets whereas DrugMatrix and TG-GATEs curate more rat datasets ( Figure 2C between databases were statistically significant for a majority of the drugs, the Jaccard scores 194 for signature overlaps were low (mostly between 0.02 and 0.04). We were not able to 195 systematically compare PharmOmics with CMAP for all drugs as done for CREEDS and 196 L1000FWD, because CMAP is an online query system (32) only feasible to query select 197 drugs. We searched atorvastatin in CMAP as an example and found that our PharmOmics 198 signature of atorvastatin from primary hepatocytes matched well with CMAP signatures of 199 the same drug from several human cancer cell lines including MCF7 (breast), HT29 (colon) 200 and VCAP (prostate), but surprisingly, not with HepG2 (hepatocellular carcinoma) which is 201 supposed to better match hepatocytes ( Supplementary Figure 2A) . The in vivo and in vitro 202 atorvastatin rat liver signatures from PharmOmics also showed different matching patterns 203 with CMAP signatures from the human cancer cell lines (supplementary Figure 2B) . Taken 204 together, our results highlight important differences between PharmOmics and major existing 205 platforms. The differences between in vivo and in vitro drug signatures support the value of 206 obtaining more physiologically relevant, species-specific and tissue-specific drug signatures. 208
Tissue-specificity of drug signatures 209
To examine tissue-specificity of drug signatures, we analyzed the overall overlaps in gene 210 signatures for each drug across tissues and. Results were visualized with UpSetR package 211 (33). shown in Figure 3A , the overlap rate in the DEGs of the same drug between tissues and 212 organs is usually less than 5%, indicating a high variability in DEGs between tissues. 213 However, shared genes across tissues at DEG and pathway levels also exist. As an example, 214 we examined the HMGCR (β-Hydroxy β -methylglutaryl-CoA receptor) inhibitor atorvastatin 215 since its mechanism is well known and atorvastatin has been broadly tested in different 216 tissues under the human species label. We found that two DEGs (TSC22D3, THBS1) were 217 shared across tissues ( Figure 3B) . These genes are involved in extracellular matrix and 218
inflammation, suggesting these processes as common targets of atorvastatin across tissues. 219
Among the pathways shared across tissues, immune related pathways were shared between 220 blood cells and liver cells but not seen in prostate cells from the urogenital system ( Figure  221 3C, Supplementary Table 2 ). Despite these overlaps, we found that the majority of the 222 DEGs were tissue-specific. Pathway analysis indicated that steroid synthesis and drug 223 metabolism pathways were altered mostly in liver, as expected, since the known target of 224 statin drugs is HMGCR, the rate limiting enzyme in cholesterol biosynthesis in liver. Blood 225 monocyte DEGs indicate changes in inflammation related pathways, while GPCR ligand 226 binding proteins were altered in prostate cancer cells. The tissue-specificity of drug 227 signatures revealed through our analysis supports tissue-specific therapeutic response or side 228 effects and the need for comprehensive maps of drug signatures across tissue systems as 229 implemented in the PharmOmics framework. 1 1
231

Species-specificity of drug signatures 232
We also compared gene signatures for each drug between species and found evidence for 233 species-specificity. Results were visualized with UpSetR package (33). As shown in Figure  234 3D, the pair-wise overlaps in DEGs between species for the same drug is generally lower 235 than 5%. Here we chose PPAR gamma receptor agonist rosiglitazone as an example because 236 this drug has datasets across human, rat, and mouse in PharmOmics and its mode of actions is 237 well-studied. As shown in Figure 3E and 3F, nine genes (CPT1C, AKR1B1, VNN1, ACSM3, 238 CD36, CPT1A, PDK4, ZNF669, ADH1C) and several pathways including PPAR signaling 239 and fatty acid, triacylglycerol, and ketone body metabolism are consistently identified from 240 liver DEGs across species ( Supplementary Table 3 ), supporting these as the major shared 241 pharmacological effectors of rosiglitazone across species. Among the species-specific 242 findings were rat-specific changes in bile acid and retinol metabolism, and adipocytokine 243 pathways in human datasets. The differences revealed between species highlight the 244 importance of understanding the physiological differences among model systems to facilitate 245 drug design with better translational potential. Our cross-species comparative studies also 246 highlight the urgent need to investigate drugs in multiple species, as only 21% of the drug-247 tissue pairs (237 out of 1140) have data from two or more species. 248 249
Implementation of a web server to enable public access to PharmOmics 250
Previously we have developed an Apache web server Mergeomics (34), which allows 251 integrative analysis of multi-omics datasets to derive disease-associated pathways, networks, 252 and network regulators (http://mergeomics.research.idre.ucla.edu/). We implemented the 
The value of PharmOmics to extract drug targets and target pathways 271
To explore the potential applications of our PharmOmics drug signatures, we evaluated 272 whether the species-and tissue-specific DEGs have the potential to retrieve drug targets and 273 target pathways. To this end, we first retrieved known drug targets for the drugs included in 274
PharmOmics from the DrugBanks database (36). Three different methods were used to 275 evaluate the potential of DEGs for drug target identification. The first method was based on 1 3 direct overlaps between DEGs and known drug targets, that is, if a known drug target was 277 directly retrieved from the DEG list it would be considered a positive hit. The second method 278 was based on overlaps in pathways, that is, whether the known pathway containing the drug 279 target was retrieved by the pathway analysis of the drug DEGs. The last method was based on 280 whether a known drug target is within the close neighborhood of drug DEGs in molecular 281 networks, including the STRING network (37) and tissue-specific Bayesian networks (BNs) 282 (Supplementary methods). 283 284 As shown in Table 1 , we found that all three drug target retrieval methods (gene overlap, 285 pathway overlap, network overlap) support that drug DEGs are more likely to detect true 286 drug targets than random genes. Compared to the gene overlap method which can retrieve 287 known drug targets at a 22.1% rate, the pathway-and network-based methods reached higher 288 target detection rates (62% for pathways, 40% for protein interaction network, 72% for liver 289 BN with matching liver DEGs, and 40% for kidney BN with mismatching liver DEGs), 290 although false positives also increased in the pathway and network-based approaches. 291
Notably, matching the tissue between DEGs and networks improved the target detection rate. 292
These results suggest that while known drug targets may not be directly detected among the 293 DEGs, pathway relatedness and network proximity in tissue specific network can be 294 informative of drug targets and can enhance the chance of target identification from drug 295
DEGs. 296 297
Drug repositioning analyses support that PharmOmics drug signatures can retrieve known 298 therapeutic drugs for various diseases 299
1 4
We hypothesized that if a drug is useful for treating a disease, the drug signatures and the 300 disease signatures will likely target similar pathways and therefore will be highly overlapping 301 or tightly connected in gene networks. To this end, we evaluated the ability of PharmOmics 302 to identify drugs for diseases based on overlaps in gene signatures matched by tissue using 303 the gene overlap-based measurement (Jaccard score) as well as a network proximity 304 measurement between drug and diseases genes which was previously applied to protein 305 interaction networks (5) (Supplementary methods). Here, we used tissue-specific BN 306 networks by testing the mean shortest distance between network hubs of the drug DEGs and 307 disease genes. We further applied Mergeomics pipeline (38) which identifies hub genes on 308 network (key drivers) in this method. Using key drivers of drug gene signatures can reduce 309 noise and improve computing speed (Supplementary Figure 3) while performing similarly 310 to drug DEGs (Figure 4A and 4B) . 311
312
We selected hyperlipidemia as a disease test case, as multiple known drugs are available as 313 positive controls to evaluate the performance of drug repositioning. We have previously 314 developed a method Mergeomics (38), which can accurately extract disease related genes, 315 pathways, and networks (39,40). Because hyperlipidemia is most relevant to LDL and the 316 liver tissue, we used Mergeomics to retrieve LDL causal genes and pathways in the liver 317 tissue based on LDL GWAS and liver genetic regulation of gene expression ( Supplementary  318   methods) . 319
320
The Jaccard score method revealed that our PharmOmics drug signatures were able to 321 differentiate anti-hyperlipidemia drugs from other drugs with 79% AUC when using in vivo 1 5 rat liver signatures (Wilcoxon signed rank test p value=0.001), 56% AUC when using in vitro 323 liver signatures (non-significant), and 74% AUC when using the aggregated rat liver 324 signatures from both in vivo and in vitro settings (referred as combined, p=0.005) ( Figure  325 4C). Among the top 5 predicted drugs are known LDL-lowering drug fluvastatin and other 326 drugs that may affect LDL including loratadine, sertraline, gefitinib, and paroxetine. 327
328
The network-based approach performed similarly as the direct gene overlap method above 329 ( Figure 4D) . The top 5 drugs predicted for hyperlipidemia based on the network approach 330 included fluvastatin, loratadine, mestranol-lynestrenol mixture, sertraline and estriol. 331
Between the network and Jaccard Score methods, 3 of the top 5 drugs from the two methods 332 overlapped, which are fluvastatin, loratadine and sertraline. Of these, fluvastatin is a known 333 HMG-CoA inhibitor for antihyperlipidemia therapy while oral contraceptives and sertraline 334 were linked with hyperlipidemia ADR (41-43). Moreover, among the 53 significant 335 predictions (out of 263 drugs) at z < -2.52 (p < 0.01) using our PharmOmics drug signatures 336
( Supplementary Table 4 ), we retrieved 6 out of the 10 approved anti-hyperlipidemia drugs 337 in the PharmOmics knowledgebase. 338 339 Using alternative hyperlipidemia signature from the Comparative Toxicogenomics database 340 (CTD) (16) to match with our PharmOmics drug signatures also showed that anti-341 hyperlipidemia drugs had better Jaccard scores and better network repositioning z-scores 342 compared to other non-hyperlipidemia drugs. In addition, in vivo drug signatures again 343 showed better repositioning performance than the in vitro and combined drug signatures in 344 the CTD-based hyperlipidemia analysis (Figure 4E, 4F ). 1 6
346
We further tested the performance of PharmOmics in retrieving known drugs for other 347 diseases. Using CTD disease signatures for diabetes and hyperuricemia, we found 348
PharmOmics signatures of known diabetes drugs had better repositioning scores than those of 349 non-diabetes drugs (Supplementary Figure 4) , and retrieved Benzbromarone as the top 350 ranked drug for hyperuricemia ( Supplementary Table 5 ). These results support the general 351 utility of PharmOmics for drug repositioning. 352
353
Better or comparable drug repositioning performance of PharmOmics compared to 354 existing platforms 355
We compared the performance of our PharmOmics drug signatures in drug repositioning with 356 that of the well-established L1000 signatures, which were mainly based on in vitro cell 357 models. We found that PharmOmics signatures achieved better repositioning results than 358 L1000 signatures aggregated across dose and regimen for both Mergeomics and CTD 359 hyperlipidemia signatures using both the Jaccard score-based and network-based 360 repositioning methods (Figure 4C-E) . Similarly, PharmOmics signatures also performed 361 better than the raw L1000 signatures when using the best performing dose and regimen 362 Figure 5) . When compared with CMAP, PharmOmics also showed better 363 performance regardless of whether the aggregate signature across CMAP cell lines 364 ( Supplementary Figure 6A, Supplementary Table 4 ) or the HEPG2-based signature was 365 used (Supplementary Figure 6B, Supplementary Table 4 ). Notably, PharmOmics was able 366 to retrieve 6 out of 10 (60%) of the known anti-hyperlipidemia drugs curated in the 367 PharmOmics database, while CMAP retrieved only 4 out of the 18 anti-hyperlipidemia drugs 1 7 examined in CMAP (22%). These results indicate the benefits of using in vivo signatures in 369 PharmOmics for drug repositioning to complement the existing cell-line based drug 370 repositioning tools to broaden drug repositioning capacity. 371
(Supplementary
372
We further compared our PharmOmics gene signatures with the CREEDS database (18) for 373 drug repositioning. Using only the best scoring signature in CREEDS to represent each drug, 374
we found comparable drug-repositioning ability between the two databases (Supplementary 375 
Use of PharmOmics to predict drugs for NAFLD 380
After establishing the performance of PharmOmics in drug repositioning using 381 hyperlipidemia, diabetes and hyperuricemia as test cases, we also applied PharmOmics to 382 predict potential drugs for NAFLD, for which there is currently no approved drugs. Using 383 NAFLD gene signatures from published studies (40,44) and the CTD database (16), we 384 predicted PPAR alpha agonists (fenofibrate and clofibrate) and PPAR gamma agonist 385 rosiglitazone to be strong matches to the NAFLD signatures ( Supplementary Table 6 ). 386 PPAR agonists have been supported as potential drugs for NAFLD (45). The beneficial 387 effects of several PPAR alpha agonists on NAFLD have been demonstrated in in vivo models 388 (46,47), but clinical evidence is inconclusive at this point (48-50). On the other hand, 389 rosiglitazone and other PPAR gamma agonists showed beneficial effects in both rodent 390 models (50-52) and clinical trials (53-56). These lines of evidence substantiate the drug 1 8
repositioning potential of our PharmOmics tool. Additional drugs predicted include aspirin 392 which was also reported beneficial in mitigating NAFLD (57) and numerous other drugs 393 (Supplementary Table 6 ) which warrant experimental testing in future studies. 394 395
PharmOmics drug signatures can predict ADRs in liver 396
We hypothesize that drugs with the same ADR likely share common gene signatures driving 397 the specific ADR events. In this case, gene signature overlaps are expected between an ADR 398 term and the drugs with the ADR. We further hypothesized that network-based modeling can 399 better characterize hidden gene signatures to improve ADR prediction, which can be tested 400 based on network distance from drug signature genes to ADR genes. We collected ADR 401 information and ADR gene signatures were first aggregated across drugs with the same ADR 402 regardless of their pharmacological classes (Supplementary methods) . We then tested 403 whether the ADR signatures can better predict drugs with the ADR than those with permuted 404 ADR labels, either based on direct gene overlaps or based on network distances (design 405 illustrated in Supplementary Figure 8A) . 406
407
We focused on rat liver drug signatures as more than 200 drugs were available for this tissue. 408
The other tissues had more limited coverage of drugs, preventing a comprehensive 409 investigation. A total of 617 ADR terms each with more than six drugs were tested. For each 410 ADR, aggregate gene signatures were obtained from all constituent drugs with the ADR. The 411 gene overlap matrix between ADR signature and individual drug signatures, or the distance 412 matrix between ADR signatures and the key drivers of drug signatures in liver Bayesian 413 network were obtained. A random forest model was built with 10-fold-5-repeat cross 1 9 validation combined with smote algorithm (58) to accommodate unbalanced ADR samples 415 (i.e., fewer drugs with an ADR than those without the ADR, Supplementary Methods) . For 416 the 617 ADR terms investigated, the distribution of the raw permuted p-values from random 417 forest models based on the gene overlapping matrix was similar to that based on the network 418 distance matrix (Supplementary Figure 8B, 8C) , both shifting towards the low p value end 419 (Kolomogorov-Smirnov test p-value <2.2e-16 against uniform distribution). However, the 420 network-based method achieved better ADR predictions with lower FDR and higher accuracy, 421 with 21 ADR terms passing FDR < 0.05 (compared to 0 ADR term based on the gene overlap 422 matrix at the same threshold) and cross-validation accuracy > 0.99 (Table 2) . Therefore, 423
PharmOmics signatures can also be used to derive ADR signatures which can predict drugs 424 with ADRs using a network-based approach. We were also able to retrieve top predictive 425 genes for many ADR terms based on the random forest models and predicted additional 426 drugs that may have these ADRs ( Table 2) . 427
428
Discussion 429
Here we present a publicly available tissue-and species-stratified drug signature database 430 along with an online web server, PharmOmics. PharmOmics fully utilizes published drug-431 related transcriptomic datasets and provides unique tissue-and species-stratified gene 432 signatures that are more reflective of in vivo activities of drugs. We also developed a 433 framework for fast drug repositioning based on tissue-specific gene network models. We 434 demonstrate that PharmOmics can be used for molecular characterization of drugs, 435 comparisons of molecular activities between tissues and between species, and various 436 The use of tissue annotation with Brenda Tissue Ontology in PharmOmics helps normalize 448 organ labels and makes datasets more comparable. Although the tree structure in Brenda 449 Tissue Ontology may assign a cell or tissue to multiple systems (for example, breast cancer 450 cell line may be categorized as both epithelial and breast organ), we prioritized the tissue 451 terms based on the relevance to toxicology to make tissue assignments unique for each 452 dataset to reduce ambiguity. The unique tissue-and species-specific analyses implemented in 453
PharmOmics allows for comprehensive molecular insight into the actions of drug molecules 454 in individual tissues and species. Our results support that different species indeed have 455 unique drug responses in addition to shared features, thereby implicating that drug responses 456 and toxicity measures obtained in animal models may require caution before directly 457 translating the insights into humans. This notion agrees with the long-observed high failure 458 2 1 rate of drug development that has primarily relied on preclinical animal models and argues 459 for improved appreciation and understanding of inter-species differences in drug actions. 460
461
We demonstrate that PharmOmics can be used to retrieve drug targets and target pathways. In 462 general, gene signatures of drugs reflect cascades of downstream events after drug 463 administration. The initial drug target(s) may or may not be captured by drug DEGs due to 464 the lack of dynamic information in the DEGs. For example, changes in the direct drug targets 465 may have occurred transiently early upon treatment, but the change may have weakened or 466 disappeared at the time of transcriptome profiling. Nevertheless, our analyses support that 467 drug signatures are more likely to contain information about drug targets as well as target 468 pathways and networks. These findings support the value of using drug signatures to reflect, 469 at least partially, the molecular mechanisms of drugs. 470
471
Previous drug repositioning studies support that protein network-based approach is powerful 472 for drug repositioning. Here we show that combining the drug transcriptomic signatures in 473 PharmOmics, particularly the in vivo signatures, with tissue-specific gene regulatory 474
Bayesian networks and gene signatures of diseases can retrieve known therapeutic drugs and 475 predict potential new therapeutic avenues. Compared to other platforms, the use of tissue-476 and species drug signatures along with network biology is a unique strength of PharmOmics, 477 which enables better performance and faster computation in repositioning. 478
479
We also demonstrate the potential of PharmOmics in ADR prediction. Although this effort is 480 limited by the small numbers of existing ADR datasets at each tissue level, we were able to 481 2 2
show the value of incorporating drug signatures with gene network models to perform ADR 482 predictions. The ADR signatures derived from our study and the predictive models from the 483 machine learning-based methods can be informative of mechanisms involved in ADRs, 484 although we acknowledge that further investigations are necessary to validate this potential. 485
486
There are several limitations in this study. First, our existing pipeline may not be able to 487 identify all of the drug datasets from GEO and ArrayExpress database. Along the same line, 488 the tissue coverage across the species is unbalanced, preventing a thorough cross-tissue and 489 cross-species comparison of drug signatures. We will keep refining the pipeline and update 490 our PharmOmics database periodically to include more datasets as they become available to 491 increase the coverage of datasets and drug signatures across tissues and species. In addition, 492 aggregating across different dosage and treatment durations may lose dose or time-specific 493 drug responses. However, we believe our approach can capture the most consistent drug 494 signatures regardless of treatment conditions, which are more representative of the general 495
properties of the drugs. The comparable performance of our platform with that of CREEDS, 496 which details dose and treatment regimens, in drug repurposing supports this notion. Lastly, 497 more comprehensive applications and experimental evaluation of PharmOmics in drug 498 repurposing for different disease areas and in ADR prediction are necessary in future studies. 499 500
Conclusion
501
We have established a new drug treatment signature database, PharmOmics, across different 502 species and tissues, which comprehensively captures the systems level in vivo activities of 503 drug molecules. In addition, we demonstrate the possible means to integrate these signatures 504 
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